MARKET

CAPR

CAPR

Capricor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.020
-0.070
-2.27%
After Hours: 3.245 +0.225 +7.45% 16:21 01/18 EST
OPEN
3.050
PREV CLOSE
3.090
HIGH
3.200
LOW
2.950
VOLUME
157.31K
TURNOVER
--
52 WEEK HIGH
8.40
52 WEEK LOW
2.750
MARKET CAP
72.93M
P/E (TTM)
-3.7083
1D
5D
1M
3M
1Y
5Y
Forget Bargains, Play 5 Stocks With Rising P/E Instead
Zacks.com · 01/02 00:25
BRIEF-Capricor Therapeutics Announces Key Updates On Its Vaccine And Therapeutic Programs For Covid-19
reuters.com · 12/13/2021 14:53
Capricor Therapeutics provides key updates on its COVID-19 vaccine programs
Capricor Therapeutics (CAPR) announces new updates on its vaccine and therapeutic development programs focused on COVID-19. The preclinical data describes the potential for Capricor’s multivalent exosome mRNA vaccine candidate for
Seekingalpha · 12/13/2021 14:43
Capricor Therapeutics Announces Updates On Its Vaccine And Therapeutic Programs For COVID-19
Capricor's Exosome-based mRNA Vaccine for SARS-CoV-2 -In-Vivo Preclinical Data Published in the Journal of Biological Chemistry- -Preclinical Data Demonstrates Strong T-Cell Response for High Conserved N
Benzinga · 12/13/2021 14:18
Here's Why Capricor (CAPR) is Poised for a Turnaround After Losing 19.3% in 4 Weeks
Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend r...
Zacks · 11/19/2021 15:00
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?
Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) is possibly approaching a major achievement in its business, so we would...
Simply Wall St. · 11/17/2021 10:24
Capricor’s CEO Dr. Linda Marbán to Serve as Keynote Speaker at TriLink Annual mRNA Day
– The Global, Virtual Event in Partnership with Genetic Engineering News (GEN) and the CRISPR Journal, Taking Place on November 16, 2021 –SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a bio...
GlobeNewswire · 11/12/2021 14:15
BRIEF-Capricor Therapeutics Reports Q3 Loss Per Share $0.17
reuters.com · 11/09/2021 22:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CAPR. Analyze the recent business situations of Capricor through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CAPR stock price target is 13.00 with a high estimate of 14.00 and a low estimate of 12.00.
High14.00
Average13.00
Low12.00
Current 3.020
EPS
Actual
Estimate
-0.18-0.14-0.09-0.05
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 43
Institutional Holdings: 2.52M
% Owned: 10.43%
Shares Outstanding: 24.15M
TypeInstitutionsShares
Increased
9
172.50K
New
6
122.55K
Decreased
6
132.61K
Sold Out
7
1.20M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-4.73%
Pharmaceuticals & Medical Research
-1.37%
Key Executives
Chairman/Executive Director/Director
Frank Litvack
President/Chief Executive Officer/Director
Linda Marban
Chief Financial Officer/Chief Accounting Officer
Anthony Bergmann
Executive Vice President/General Counsel
Karen Krasney
Director
Karimah Es Sabar
Independent Director
Earl Collier
Independent Director
George Dunbar
Independent Director
Louis Manzo
Independent Director
David Musket
No Data
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company. The Company is focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of diseases. It consists of cell therapy program, including CAP-1002 with Duchenne muscular dystrophy program and CAP-1002 with COVID-19 (SARS-CoV-2) program. It also includes exosomes program, such as exosome-based vaccines, exosome-based therapeutics and CDC-Derived Exosomes (CAP-2003). Duchenne muscular dystrophy program has completed HOPE-2, a Phase II clinical trial in the United States with its product candidate.CAP-1002 is a cardiac cell derived therapy used to treat patients with late-stage Duchenne muscular dystrophy. The Company has received the United States Food and Drug Administration (FDA) acceptance of its investigational new drug (IND) application for a clinical study of CAP-1002 in patients with severe or critical COVID-19.

Webull offers kinds of Capricor Therapeutics Inc stock information, including NASDAQ:CAPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CAPR stock methods without spending real money on the virtual paper trading platform.